PubRank

Lawrence H Schwartz

Author PubWeight™ 151.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007 6.65
2 Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014 6.61
3 Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014 6.10
4 Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004 4.68
5 Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010 4.64
6 Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007 3.74
7 Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 2009 3.30
8 Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009 3.11
9 Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 2011 3.05
10 Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2009 2.97
11 Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009 2.89
12 The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys 2011 2.48
13 Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005 2.44
14 NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009 2.40
15 Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003 2.36
16 Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012 2.36
17 Lung cancer: computerized quantification of tumor response--initial results. Radiology 2006 2.23
18 Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004 2.13
19 Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg 2003 2.09
20 A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010 1.98
21 Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2008 1.94
22 NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009 1.86
23 Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology 2012 1.75
24 Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 2006 1.71
25 Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 2011 1.56
26 Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011 1.55
27 Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 2012 1.54
28 Marker-controlled watershed for lymphoma segmentation in sequential CT images. Med Phys 2006 1.52
29 Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009 1.50
30 Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology 2011 1.48
31 Pulmonary metastases: effect of CT section thickness on measurement--initial experience. Radiology 2005 1.48
32 Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005 1.44
33 Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol 2005 1.42
34 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 2006 1.40
35 Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 2005 1.35
36 Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging 2012 1.34
37 Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology 2007 1.32
38 Automated quantification of body fat distribution on volumetric computed tomography. J Comput Assist Tomogr 2006 1.31
39 Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med 2008 1.30
40 Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010 1.28
41 When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012 1.28
42 Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 2011 1.24
43 A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 2008 1.24
44 Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003 1.22
45 Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol 2012 1.21
46 Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 2013 1.21
47 Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 2009 1.21
48 Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. Med Phys 2013 1.18
49 Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol 2013 1.17
50 Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology 2008 1.16
51 Automatic detection of small lung nodules on CT utilizing a local density maximum algorithm. J Appl Clin Med Phys 2003 1.15
52 Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008 1.15
53 Liver segmentation for CT images using GVF snake. Med Phys 2005 1.15
54 Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011 1.13
55 Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011 1.10
56 Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010 1.07
57 Shape-constraint region growing for delineation of hepatic metastases on contrast-enhanced computed tomograph scans. Invest Radiol 2006 1.04
58 CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011 1.03
59 A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004 1.03
60 Lymph node segmentation from CT images using fast marching method. Comput Med Imaging Graph 2004 1.00
61 Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours. Cancer Imaging 2012 1.00
62 A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol 2005 0.98
63 Test-retest reproducibility analysis of lung CT image features. J Digit Imaging 2014 0.98
64 Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol 2014 0.96
65 Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009 0.96
66 Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009 0.94
67 Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. Lung Cancer 2011 0.93
68 Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg 2007 0.92
69 Shoulder impingement presenting as neck pain. J Bone Joint Surg Am 2003 0.92
70 Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006 0.91
71 Update on colorectal cancer imaging. Radiol Clin North Am 2007 0.91
72 Automated matching and segmentation of lymphoma on serial CT examinations. Med Phys 2007 0.91
73 Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecol Oncol 2008 0.91
74 Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma. Skeletal Radiol 2008 0.91
75 Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. Med Phys 2009 0.90
76 Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008 0.89
77 A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 2011 0.89
78 Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging 2009 0.89
79 Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol 2013 0.89
80 The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am 2007 0.89
81 How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 2007 0.88
82 Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer 2008 0.88
83 An automatic method for ground glass opacity nodule detection and segmentation from CT studies. Conf Proc IEEE Eng Med Biol Soc 2006 0.86
84 Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol 2008 0.86
85 Routine editing of trainee-generated radiology reports: effect on style quality. Acad Radiol 2003 0.85
86 Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer. J Nucl Med 2014 0.84
87 Retained seminal vesicles after radical prostatectomy: frequency, MRI characteristics, and clinical relevance. AJR Am J Roentgenol 2006 0.84
88 Time to tumor growth: a model end point and new metric system for oncology clinical trials. J Clin Oncol 2013 0.84
89 Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007 0.83
90 Contemporary imaging in sarcoma. Oncologist 2009 0.83
91 Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients. Pediatr Radiol 2010 0.81
92 The imaging viewpoint: how imaging affects determination of progression-free survival. Clin Cancer Res 2013 0.80
93 Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol 2013 0.80
94 Mesenteric adenopathy in patients with prostate cancer: frequency and etiology. AJR Am J Roentgenol 2002 0.80
95 Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. J Magn Reson Imaging 2012 0.78
96 Evaluation of focal liver lesions: fast-recovery fast spin echo T2-weighted MR imaging. Clin Imaging 2006 0.77
97 Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy. Mol Imaging 2013 0.76
98 Automatic detection and segmentation of ground glass opacity nodules. Med Image Comput Comput Assist Interv 2006 0.75
99 Response phenotype as a predictive biomarker to guide treatment with targeted therapies. J Clin Oncol 2013 0.75
100 31P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization. J Magn Reson Imaging 2011 0.75
101 Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2010 0.75
102 Measuring hepatic metastases to colon cancer. AJR Am J Roentgenol 2006 0.75
103 Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. NMR Biomed 2012 0.75
104 Recurrence patterns of intraductal papillary mucinous neoplasms of the pancreas on enhanced computed tomography. J Comput Assist Tomogr 2009 0.75
105 MR imaging after surgery for musculoskeletal neoplasm. Semin Musculoskelet Radiol 2002 0.75
106 Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Sci Rep 2017 0.75